Lung metastasis following temporary discontinuation of lenvatinib and tislelizumab in hepatocellular carcinoma: A case report

Figure 4 Trends of tumor markers during the treatment. A: Alpha-fetoprotein levels of different periods, drastic decrease could be observed during the combined therapy, while a decrease was observed after supplementary transcatheter arterial chemoembolization on February 4, 2024, replacing hepatic arterial infusion chemotherapy with lenvatinib and tislelizumab; B: Prothrombin Induced by Vitamin K Absence or Antagonism Type II levels of different periods, continuous decline was observed. HAIC: Hepatic arterial infusion chemotherapy; TACE: Transcatheter arterial chemoembolization; AFP: Alpha-fetoprotein; PIVKA-II: Prothrombin Induced by Vitamin K Absence or Antagonism Type II.